{"id":431340,"date":"2024-06-17T00:00:00","date_gmt":"2024-06-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0007-biopharma-chronic-obstructive-pulmonary-disease-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:29:37","modified_gmt":"2026-03-31T10:29:37","slug":"epidim0007-biopharma-chronic-obstructive-pulmonary-disease-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0007-biopharma-chronic-obstructive-pulmonary-disease-epidemiology-mature-markets\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of chronic obstructive pulmonary disease (<abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>?<\/li>\n<li>In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>, how many in each country have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 24 <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>Total prevalent cases of <abbr title=\"Global Initiative for Chronic Obstructive Lung Disease\">GOLD<\/abbr>-defined <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>Prevalent cases of spirometric-negative <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"Global Initiative for Chronic Obstructive Lung Disease\">GOLD<\/abbr>-defined <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of mild to moderate <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of severe to very severe <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> with comorbid lifetime asthma.<\/li>\n<li>Prevalent cases of eosinophilic <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-431340","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-therapy-areas-respiratory","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/431340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/431340\/revisions"}],"predecessor-version":[{"id":431683,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/431340\/revisions\/431683"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=431340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}